GENERAL
Aurobindo Pharma Gets USFDA Nod For Dapagliflozin-Metformin Combo
Aurobindo Pharma Ltd has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Dapagliflozin and Metformin Hydrochloride extended-release tablets in multiple strengths such as 5 mg/500 mg, 5 mg/1000 mg, 10 mg/500 mg, and 10 mg/1000 mg. The approved formulation is bioequivalent and therapeutically equivalent to the reference listed […]
CW Bureau
·
Apr 7, 2026
GENERAL
CuraTeQ Biologics Reports Positive Phase 3 Results For BP11 Biosimilar
CuraTeQ Biologics Pvt Ltd, a wholly owned subsidiary of Aurobindo Pharma Ltd, has announced positive top-line results from its Phase 3 clinical study of BP11, an investigational biosimilar to Xolair (omalizumab). Study meets primary endpoints in CSU patients According to the company, the study successfully met all primary endpoints, demonstrating high comparability with the reference […]
CW Bureau
·
Apr 6, 2026
GENERAL
Aurobindo Arm Eugia Secures USFDA Nod For Everolimus Tablets
Aurobindo Pharma has strengthened its US generics portfolio after its wholly owned subsidiary, Eugia Pharma Specialities, received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Everolimus tablets in multiple strengths. The approval covers Everolimus tablets in 0.25 mg, 0.5 mg, 0.75 mg and 1 mg strengths. The product is […]
CW Bureau
·
Feb 26, 2026
